OBJECTIVE： To compare the preventive effects and safety of aspirin and clopodogrel respectively used for vascular restenosis after coronary intimal striping with coronary artery bypass grafting. METHODS： 110 patients with coronary atherosclerotic heart disease were divided into aspirin group （55 cases） and clopodogrel group （55 cases）. All patients intravenously micro-pumped Nitroglycerin injection 10 mg+5％ Glucose injection totally 20 mL for maintaining 48-72 h after coronary intimal striping with coronary artery bypass grafting， intravenously pumped Dopamine hydrochloride injection 1-5 μg/kg if necessary. Unplug the endotracheal tube after surgery， patients received Cefuroxime sodium for injection 1.5 g adding into Sterile water for injection 50 mL， intravenous injection， 3 times a day， for 2-3 d. Meanwhile， patients were orally given Rosuvastatin calcium tablet 10 mg 30 min after daily dinner， 8-week was a course， for 3 courses. Based on it， aspirin group received Aspirin enteric-coated tablet with initial dose of 300 mg， once a day， orally taking 100 mg from the second day， once a day， for 6 months； clopodogrel group received Clopidogrel hydrogen sulfate tablet with initial dose of 300 mg， once a day， orally taking 75 mg from the second day， once a day， for 6 months. Graft patency rate， and platelet aggregation rate， platelet aggregation compliance rate， fibrinogen （Fg）， D-dimer （D-D）， platelet count （PLT）， tissue-type plasminogen activator （t-PA） before and after treatment， and the incidence of adverse reactions in 2 groups were observed. RESULTS： There were no significant differences in the graft patency rate and incidence of adverse reactions in 2 groups （P＞0.05）. Before treatment， there were no significant differences in platelet aggregation rate， platelet aggregation compliance rate， Fg， D-D， PLT and t-PA in 2 groups （P＞0.05）. After treatment， platelet aggregation rate， Fg and D-D level in 2 groups were significantly lower than before， platelet aggregation compliance rate， PLT and t-PA level were significantly higher than before， with statistical significance （P＜0.05）， while there were no significant differences between 2 groups （P＞0.05）. CONCLUSIONS： Based on conventional treatment， both aspirin and clopidogrel used for coronary intimal striping with coronary artery bypass grafting can inhibit platelet aggregation， reduce thrombosis， maintain vascular patency and prevent vascular restenosis， with good safety.